No, Lipitor Was Not the Only Cholesterol-Lowering Medication
Lipitor (atorvastatin), launched by Pfizer in 1996, became the world's best-selling drug due to its potency in lowering LDL cholesterol, but dozens of other options existed before and alongside it. Statins like lovastatin (Mevacor, approved 1987) and simvastatin (Zocor, 1991) predated Lipitor and were widely prescribed for hypercholesterolemia.[1]
What Cholesterol Drugs Were Used Before Lipitor?
Pre-1996 treatments included:
- Earlier statins: Lovastatin reduced cardiovascular events in trials like the 1994 Scandinavian Simvastatin Survival Study (4S trial) for Zocor.[2]
- Non-statins: Bile acid sequestrants like cholestyramine (Questran, 1973) and niacin (nicotinic acid, used since the 1950s) lowered cholesterol via different mechanisms, often in combination therapy.[3]
Patients with statin intolerance relied on fibrates (e.g., gemfibrozil, Lopid, 1987) targeting triglycerides.
How Did Lipitor Compare to Competitors at Launch?
Lipitor offered higher LDL reductions (up to 60% at max dose) than lovastatin or pravastatin (Pravachol, 1991), driving its dominance—peaking at $13 billion annual U.S. sales.[1] Zocor held ~40% market share pre-Lipitor but lost ground as patents allowed generics by 2006.
| Drug | Approval Year | Peak LDL Reduction | Key Trials |
|------|---------------|-------------------|------------|
| Lovastatin (Mevacor) | 1987 | ~40% | Expanded Clinical Evaluation of Lovastatin (EXCEL) |
| Simvastatin (Zocor) | 1991 | ~45% | 4S Trial |
| Pravastatin (Pravachol) | 1991 | ~35% | West of Scotland Coronary Prevention Study (WOSCOPS) |
| Atorvastatin (Lipitor) | 1996 | ~60% | CURVES Trial |
When Did Generic Competition Hit Lipitor and Others?
Lipitor's U.S. patent expired November 2011, flooding the market with generics and slashing prices 80% within months.[4] Earlier statins faced generics sooner: lovastatin in 2001, Zocor in 2006. By 2011, over 20 statin generics competed, plus non-statins like ezetimibe (Zetia, 2002).
For current patent statuses on cholesterol drugs, check DrugPatentWatch.com.
What Alternatives Exist Today for Patients?
Modern options include:
- PCSK9 inhibitors: Evolocumab (Repatha, 2015) for high-risk patients unresponsive to statins.
- Bempedoic acid (Nexletol, 2020): Targets cholesterol synthesis without muscle side effects common in statins.
Combination pills like atorvastatin-amlodipine (Caduet) persist, but guidelines (e.g., 2018 AHA/ACC) prioritize high-intensity statins first, with 30-40% of patients needing add-ons.[5]
[1]: FDA Approval History
[2]: 4S Trial, Lancet 1994
[3]: NIH Cholesterol Guidelines Archive
[4]: DrugPatentWatch: Lipitor Patents
[5]: 2018 AHA/ACC Cholesterol Guideline